Go to main content
Tricals - The highway towards a cure
Motor neuron disease unit

University and Polytechnic Hospital La Fe

Spain - Valencia

This multidisciplinary unit is the reference center for the treatment of MND patients in the Valencian region, providing care to a population of five million inhabitants.

The motor neuron disease unit of Hospital la Fe is the reference center in the Valencian region for the treatment of MND patients (ALS, SMA, etc…). Each year, more than 60 new patients and 160 prevalent patients are treated in this multidisciplinary unit. The main areas of expertise in research include the analysis of those factors influencing the diagnostic delay and prognosis of ALS patients, the development and validation of outcome measures for ALS patients, the search of biomarkers, the study of the genetic and environmental risk factors of ALS and the search of new treatments. In the last 10 years, we have participated in more than 20 research projects and in more than 30 clinical trials in motor neuron diseases.

Specialists in this centre

Juan Francisco Vázquez-Costa

Neurologist, Coordinator MND Unit

Location

Avda Fernando Abril Martorell 106, 46026,Valencia,Spain

Contact

Current trials in this centre

Open for participation

ATLAS

Phase 3
Industry
SOD1

This trial evaluates the efficacy and safety and of an investigational drug for pre-symptomatic carriers of the SOD1 gene.

More about this trial

Closed for participation

DAZALS

Phase 2
Industry
No

In this study, an investigational oral drug named dazucorilant (also called CORT113176) is being studied in people living with ALS.

More about this trial

Closed for participation

Lighthouse 2

Phase 3
IIT
No

The Lighthouse 2 study is a phase 3 clinical trial in which we will investigate the efficacy of the drug Triumeq.

More about this trial

Archived

PHOENIX

Phase 3
Industry
No

Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035'.

More about this trial

Archived

CardinALS

Phase 2
Industry
No

The CARDINALS clinical research study is evaluating a study drug (Utreloxastat) to see if it can help slow ALS symptoms.

More about this trial

Archived

ADORE

Phase 3
Industry
No

Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of FNP122 for people with ALS.

More about this trial

Archived

APL2-ALS-206 trial

Phase 2
Industry
No

In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS.

More about this trial

Archived

COURAGE-ALS

Phase 3
Industry
No

In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS.

More about this trial

Archived

ALXN1210-ALS-308 trial

Phase 3
Industry
No

This study is designed to test the efficacy and safety of intravenous Ravulizumab in patients with ALS.

More about this trial

Contact this centre

If you would like to contact us or register for a trial, leave your details here.